ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
항신생물제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에 CAGR은 8.8%를 나타낼 것으로 예측되고 1,976억 8,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 환자 교육 및 인식 제고, 정부 주도 정책, 맞춤형 암 치료에 대한 수요 증가, 암 치료에서 삶의 질에 대한 주력 증가 등에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 종양학 연구 발전, 표적 치료제 개발, 생명공학 혁신, 진단 도구 발전 등이 포함됩니다.
향후 5년간 8.8% 성장률 전망은 해당 시장에 대한 이전 추정치 대비 0.2% 소폭 하향 조정된 수치입니다. 이 같은 하향 조정은 주로 미국과 타국 간 관세 영향 때문입니다. 무역 긴장은 영국 및 벨기에에서 생산되는 폴리-ADP-리보스 폴리머레이스 억제제(PARP 억제제)와 같은 표적 항신생물제 가격 상승을 초래하여 미국 종양학 병원에 부정적 영향을 미칠 수 있으며, 이는 정밀의학 접근 지연과 암 치료 비용 증가로 이어질 수 있습니다. 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 효과는 더욱 광범위하게 나타날 것입니다.
암 발병률 증가는 향후 항신생물제 시장 확장을 촉진할 것으로 예상됩니다. 암은 신체 내 거의 모든 장기나 조직에서 발생할 수 있는 질병군으로, 비정상 세포가 통제 불가능하게 증식하여 정상 경계를 넘어 다른 장기로 전이되거나 주변 조직을 침범할 때 발생합니다. 항신생물제는 DNA 손상 유발, 세포주기 교란, 핵심 세포 과정 방해 등 다양한 기전을 통해 암세포의 성장과 분열을 억제하므로 암 치료에 핵심적 역할을 합니다. 예를 들어, 2024년 2월 프랑스에 본부를 둔 국제암연구소(IARC)는 2050년까지 전 세계 암 환자 수가 2022년 추정치인 2,000만 명 대비 77% 증가한 3,500만 명을 넘어설 것으로 전망했습니다. 결과적으로 증가하는 암 환자 수는 항신생물제 시장 성장을 촉진하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 항신생물제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 항신생물제 시장 : 성장률 분석
세계의 항신생물제 시장 실적 : 규모와 성장(2019-2024년)
세계의 항신생물제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 항신생물제 : 총 잠재시장 규모(TAM)
제6장 시장 세분화
세계의 항신생물제 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
알킬화제
항대사제
호르몬 및 길항제
기타
세계의 항신생물제 시장 : 질환 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
소화기암
전립선암
폐암
유방암
기타 질병의 유형
세계의 항신생물제 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 항신생물제 시장, 호르몬 및 길항제 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
에스트로겐 및 항에스트로겐
안드로겐 및 항안드로겐
글루코코르티코이드
세계의 항신생물제 시장, 기타 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
빈카 알칼로이드
탁산
항생제 항종양제
표적 치료제
제7장 지역별, 국가별 분석
세계의 항신생물제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 항신생물제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
항신생물제 시장 : 경쟁 구도
항신생물제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Bristol-Myers Squibb Company
AstraZeneca PLC
Fresenius SE & Co. KGaA
Takeda Pharmaceutical Company Limited
Boehringer Ingelheim International GmbH
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
Eisai Co. Ltd.
Sun Pharmaceutical Industries Limited
Ipsen SA
Cipla Limited
Dr. Reddy's Laboratories Ltd.
Intas Pharmaceuticals Limited
Hikma Pharmaceuticals PLC
Gland Pharma Limited
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
항신생물제 시장(2029년) : 새로운 기회를 제공하는 국가
항신생물제 시장(2029년) : 새로운 기회를 제공하는 부문
항신생물제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Anti-neoplastic agents refer to drugs that inhibit or destroy abnormal tissue growth, specifically targeting and combating cancerous cells in the body. They have a vital role in cancer treatment by disrupting the processes involved in tumor development and progression.
The main types of anti-neoplastic agents are alkylating agents, antimetabolites, hormones and antagonists and miscellaneous. Alkylating agents are a class of chemical compounds that can add alkyl groups to DNA, RNA and proteins, disrupting their normal function and interfering with cell replication. These are used to treat several diseases, including gastrointestinal cancer, prostate cancer, lung cancer, breast cancer and others and are used by various end users, such as hospitals, clinics, cancer rehabilitation centers and ambulatory surgical centers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The anti-neoplastic agents market research report is one of a series of new reports from The Business Research Company that provides anti-neoplastic agents market statistics, including anti-neoplastic agent industry global market size, regional shares, competitors with an anti-neoplastic agent market share, detailed anti-neoplastic agents market segments, market trends and opportunities and any further data you may need to thrive in the anti-neoplastic agent industry. This anti-neoplastic agent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The anti-neoplastic agents market size has grown strongly in recent years. It will grow from $130.01 billion in 2024 to $140.9 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing cancer incidence, growing demand for therapies, rising demand for minimally invasive cancer treatments, demand for affordable anti-neoplastic treatments.
The anti-neoplastic agents market size is expected to see strong growth in the next few years. It will grow to $197.68 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to patient education and awareness, government initiative, growing demand for personalized cancer treatment, growing focus on quality of life in cancer treatment. Major trends in the forecast period include advancements in oncology research, development of targeted therapies, biotechnology innovation, advancements in diagnostic tools.
The forecast of 8.8% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oncology hospitals by inflating prices of targeted cancer therapies like poly adp-ribose polymerase inhibitors produced in the UK and Belgium, resulting in delayed precision medicine access and higher cancer treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The growing incidence of cancer is anticipated to drive the expansion of the antineoplastic agent market in the future. Cancer refers to a group of diseases that can arise in nearly any organ or tissue within the body, occurring when abnormal cells grow uncontrollably, surpass their usual boundaries, and either spread to other organs or invade surrounding areas. Antineoplastic agents are crucial in the treatment of cancer as they work to prevent the growth and division of cancerous cells through various mechanisms, such as causing DNA damage, disrupting the cell cycle, and interfering with key cellular processes. For example, in February 2024, the International Agency for Research on Cancer (IARC), a global organization based in France that fosters international cooperation in cancer research, projected that the global cancer burden will exceed 35 million by 2050, representing a 77% increase from the estimated 20 million in 2022. As a result, the rising number of cancer cases is fueling the growth of the antineoplastic agent market.
The growth of the anti-neoplastic agent market is expected to be driven by an increase in investment in cancer research. This investment involves allocating financial resources to support scientific endeavors aimed at studying, preventing, diagnosing, and treating cancer. The additional funding for cancer research enables pharmaceutical and biotechnology companies to explore, develop, and rigorously test new anti-neoplastic agents, which includes identifying potential drug targets and creating candidate compounds. For example, in March 2022, the Australian Department of Health and Aged Care allocated $893.5 million to improve cancer services and outcomes. A portion of this investment, $329.4 million, is earmarked for new cancer drugs like Trodelvy, Lynparza, and Mylotarg, which can potentially benefit hundreds of patients annually. Consequently, the increased investment in cancer research is poised to drive the growth of the anti-neoplastic agent market.
Leading companies in the field of anti-neoplastic agents are dedicated to the development of clinical practices to maintain their market position. For instance, in March 2022, Novartis AG, a pharmaceutical company headquartered in Switzerland, announced the approval of Pluvicto by the Food and Drug Administration (FDA). Pluvicto is the first targeted radioligand therapy approved for the treatment of progressive metastatic castration-resistant prostate cancer (mCRPC) that is positive for PSMA (Prostate-specific membrane antigen). The recommended treatment regimen involves administering 7.4 GBq (200 mCi) of Pluvicto intravenously every six weeks for a maximum of six doses, with treatment cessation upon disease progression or if intolerable toxicity occurs, whichever happens first. Patient selection for Pluvicto treatment in previously treated mCRPC should be based on the assessment of PSMA expression in tumors, employing Locametz or another authorized PSMA-11 imaging agent.
In August 2022, Ipsen SA, a biopharmaceutical company headquartered in France, completed the acquisition of Epizyme Inc. for a total of $247 million. This strategic move by Ipsen is intended to broaden its oncology portfolio by incorporating Tazverik, an innovative EZH2 inhibitor that offers a chemotherapy-free treatment option. Epizyme Inc., based in the United States, is a biopharmaceutical company known for its contributions in the field of anti-neoplastic agents.
Major companies operating in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.
North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the anti-neoplastic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The anti-neoplastic agents market consists of sales of antitumor antibiotics, microtubule inhibitors and topoisomerase inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Anti-Neoplastic Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on anti-neoplastic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for anti-neoplastic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anti-neoplastic agents market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Alkylating Agents; Antimetabolites; Hormones And Antagonists; Miscellaneous
2) By Disease Type: Gastrointestinal Cancer; Prostate Cancer; Lung Cancer; Breast Cancer; Other Disease Types
3) By End User: Hospitals; Clinics; Cancer Rehabilitation Centers; Ambulatory Surgical Centers
Subsegments:
1) By Alkylating Agents: Nitrogen Mustards; Alkyl Sulfonates; Nitrosoureas; Triazines
2) By Antimetabolites: Purine Analogues; Pyrimidine Analogues; Folate Antagonists
3) By Hormones and Antagonists: Estrogens and Antiestrogens; Androgens and Antiandrogens; Glucocorticoids
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Anti-Neoplastic Agents Market Characteristics
3. Anti-Neoplastic Agents Market Trends And Strategies
4. Anti-Neoplastic Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Anti-Neoplastic Agents Growth Analysis And Strategic Analysis Framework
5.1. Global Anti-Neoplastic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Anti-Neoplastic Agents Market Growth Rate Analysis
5.4. Global Anti-Neoplastic Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Anti-Neoplastic Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Anti-Neoplastic Agents Total Addressable Market (TAM)
6. Anti-Neoplastic Agents Market Segmentation
6.1. Global Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alkylating Agents
Antimetabolites
Hormones And Antagonists
Miscellaneous
6.2. Global Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gastrointestinal Cancer
Prostate Cancer
Lung Cancer
Breast Cancer
Other Disease Types
6.3. Global Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Cancer Rehabilitation Centers
Ambulatory Surgical Centers
6.4. Global Anti-Neoplastic Agents Market, Sub-Segmentation Of Alkylating Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nitrogen Mustards
Alkyl Sulfonates
Nitrosoureas
Triazines
6.5. Global Anti-Neoplastic Agents Market, Sub-Segmentation Of Antimetabolites, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Purine Analogues
Pyrimidine Analogues
Folate Antagonists
6.6. Global Anti-Neoplastic Agents Market, Sub-Segmentation Of Hormones and Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Estrogens and Antiestrogens
Androgens and Antiandrogens
Glucocorticoids
6.7. Global Anti-Neoplastic Agents Market, Sub-Segmentation Of Miscellaneous, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vinca Alkaloids
Taxanes
Antibiotic Antineoplastics
Targeted Therapy Agents
7. Anti-Neoplastic Agents Market Regional And Country Analysis
7.1. Global Anti-Neoplastic Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Anti-Neoplastic Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
